Literature DB >> 9664852

Absence of the adhesio interthalamica as a marker of early developmental neuropathology in schizophrenia: an MRI and postmortem histologic study.

P J Snyder1, B Bogerts, H Wu, R M Bilder, K S Deoras, J A Lieberman.   

Abstract

Several recent studies have reported an association between midline cerebral malformations (e.g., corpus callosum, cavum septum pellucidum) and schizophrenia. The authors investigated whether absence of the adhesio interthalamica (AI), a midline structure that develops in concert with prominent features of the ventricular system soon after the bridge from the late embryonic stages to early fetal life, might constitute a marker of early developmental neuropathologic changes in schizophrenia. Eighty-two patients (54 men, 28 women) with a diagnosis of first-episode schizophrenia (FES) were recruited from consecutive admissions to a psychiatric inpatient service. Fifty-two healthy control subjects (30 men, 22 women) were recruited and matched to the patient sample on distributions of sex and age. Magnetic resonance imaging studies were performed, and the presence versus absence of the AI was determined for each subject. The length and volume of the third ventricle were measured for each subject. The AI was found to be absent more often among patients with FES compared with control subjects, and patients without an observable AI also had larger third-ventricle volumes. These differences in presence or absence of the AI observed in vivo (but not in a comparable postmortem sample of histologically fixed and prepared brain slices), which are likely related to third-ventricle enlargement, may represent yet another early developmental marker of cerebral malformation among patients with FES.

Entities:  

Mesh:

Year:  1998        PMID: 9664852     DOI: 10.1111/jon199883159

Source DB:  PubMed          Journal:  J Neuroimaging        ISSN: 1051-2284            Impact factor:   2.486


  8 in total

1.  Cavum septum pellucidum in schizophrenia: clinical and neuropsychological correlates.

Authors:  Laura A Flashman; Robert M Roth; Heather S Pixley; Howard B Cleavinger; Thomas W McAllister; Robert Vidaver; Andrew J Saykin
Journal:  Psychiatry Res       Date:  2007-02-07       Impact factor: 3.222

Review 2.  A review of MRI findings in schizophrenia.

Authors:  M E Shenton; C C Dickey; M Frumin; R W McCarley
Journal:  Schizophr Res       Date:  2001-04-15       Impact factor: 4.939

3.  Microstructural thalamic changes in schizophrenia: a combined anatomic and diffusion weighted magnetic resonance imaging study.

Authors:  Nivedita Agarwal; Gianluca Rambaldelli; Cinzia Perlini; Nicola Dusi; Omer Kitis; Marcella Bellani; Roberto Cerini; Miriam Isola; Amelia Versace; Matteo Balestrieri; Anna Gasparini; Roberto Pozzi Mucelli; Michele Tansella; Paolo Brambilla
Journal:  J Psychiatry Neurosci       Date:  2008-09       Impact factor: 6.186

4.  Thalamic Massa Intermedia in Children with and without Midline Brain Malformations.

Authors:  M T Whitehead; N Najim
Journal:  AJNR Am J Neuroradiol       Date:  2020-02-27       Impact factor: 3.825

5.  A magnetic resonance imaging study of adhesio interthalamica in clinical subtypes of schizophrenia.

Authors:  Hossein Haghir; Naghmeh Mokhber; Mahmoud-Reza Azarpazhooh; Mehri Baghban Haghighi; Mahla Radmard
Journal:  Indian J Psychiatry       Date:  2013-04       Impact factor: 1.759

6.  Prevalence and Characteristics of Cavum Septum Pellucidum in Schizophrenia: A 16 Slice Computed Tomography Study.

Authors:  Sourav Khanra; Naveen Kumar Srivastava; Vivek Chail; Christoday Raja Jayant Khess
Journal:  Indian J Psychol Med       Date:  2016 Sep-Oct

7.  The double massa intermedia.

Authors:  Serhat Baydin; Abuzer Gungor; Oguz Baran; Necmettin Tanriover; Albert L Rhoton
Journal:  Surg Neurol Int       Date:  2016-03-29

8.  Structural connectivity of the human massa intermedia: A probabilistic tractography study.

Authors:  Alireza Borghei; Irem Kapucu; Robert Dawe; Mehmet Kocak; Sepehr Sani
Journal:  Hum Brain Mapp       Date:  2021-01-20       Impact factor: 5.038

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.